Johnson & Johnson (JNJ) Projected to Post Earnings on Wednesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 16th. Analysts expect the company to announce earnings of $2.65 per share and revenue of $22.85 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $1.44 during trading on Thursday, reaching $157.72. The company's stock had a trading volume of 6,719,599 shares, compared to its average volume of 8,060,895. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a market cap of $379.48 billion, a price-to-earnings ratio of 17.54, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The firm has a 50 day moving average of $153.67 and a 200-day moving average of $154.27. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.30%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Bank of America reduced their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,876 shares of the company's stock after buying an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.